332 related articles for article (PubMed ID: 19137772)
1. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
[TBL] [Abstract][Full Text] [Related]
2. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
[TBL] [Abstract][Full Text] [Related]
3. Treatment of facial lipoatrophy via autologous fat transfer.
Cohen G; Treherne A
J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
[TBL] [Abstract][Full Text] [Related]
4. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
5. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
Pavicic T; Ruzicka T; Korting HC; Gauglitz G
J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
[TBL] [Abstract][Full Text] [Related]
6. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
Orentreich D; Leone AS
Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
Burgess CM; Quiroga RM
J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
[TBL] [Abstract][Full Text] [Related]
9. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
10. A comparison of lipoatrophy and aging: volume deficits in the face.
Coleman S; Saboeiro A; Sengelmann R
Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
[TBL] [Abstract][Full Text] [Related]
11. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
[TBL] [Abstract][Full Text] [Related]
12. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
13. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
14. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse).
Comite SL; Liu JF; Balasubramanian S; Christian MA
Dermatol Online J; 2004 Oct; 10(2):2. PubMed ID: 15530292
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
[TBL] [Abstract][Full Text] [Related]
17. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
[TBL] [Abstract][Full Text] [Related]
18. Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy.
Denton AB; Tsaparas Y
Otolaryngol Head Neck Surg; 2007 Apr; 136(4):563-7. PubMed ID: 17418252
[TBL] [Abstract][Full Text] [Related]
19. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
[TBL] [Abstract][Full Text] [Related]
20. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
Walther RA
Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
